Search

Your search keyword '"Di Fusco S"' showing total 41 results
Start Over Author "Di Fusco S"
41 results on '"Di Fusco S"'

1. Multidistrict atherosclerotic disease: epidemiological and clinical framework

Author

Di Fusco, S, Abrignani, M, Amico, A, Luca, F, Mureddu, G, Ceravolo, R, Temporelli, P, Acerbo, V, Altamura, V, Baccino, D, Binaghi, G, Bugani, G, Cesaro, A, Ciccirillo, F, Cocozza, S, D'Errigo, P, Di Martino, M, Di Nora, C, Fileti, L, Lopriore, V, Maloberti, A, Monitillo, F, Gulizia, M, Grimaldi, M, Gabrielli, D, Oliva, F, Colivicchi, F, Di Fusco S. A., Abrignani M. G., Amico A. F., Luca F., Mureddu G. F., Ceravolo R., Temporelli P. L., Acerbo V., Altamura V., Baccino D., Binaghi G., Bugani G., Cesaro A., Ciccirillo F., Cocozza S., D'Errigo P., Di Martino M., Di Nora C., Fileti L., Lopriore V., Maloberti A., Monitillo F., Gulizia M. M., Grimaldi M., Gabrielli D., Oliva F., Colivicchi F., Di Fusco, S, Abrignani, M, Amico, A, Luca, F, Mureddu, G, Ceravolo, R, Temporelli, P, Acerbo, V, Altamura, V, Baccino, D, Binaghi, G, Bugani, G, Cesaro, A, Ciccirillo, F, Cocozza, S, D'Errigo, P, Di Martino, M, Di Nora, C, Fileti, L, Lopriore, V, Maloberti, A, Monitillo, F, Gulizia, M, Grimaldi, M, Gabrielli, D, Oliva, F, Colivicchi, F, Di Fusco S. A., Abrignani M. G., Amico A. F., Luca F., Mureddu G. F., Ceravolo R., Temporelli P. L., Acerbo V., Altamura V., Baccino D., Binaghi G., Bugani G., Cesaro A., Ciccirillo F., Cocozza S., D'Errigo P., Di Martino M., Di Nora C., Fileti L., Lopriore V., Maloberti A., Monitillo F., Gulizia M. M., Grimaldi M., Gabrielli D., Oliva F., and Colivicchi F.

Abstract

Atherosclerosis is a systemic disease that can involve different arterial districts. Traditionally, the focus of cardiologists has been on the diagnosis and treatment of atherosclerotic coronary artery disease (CAD). However, atherosclerosis localization in other districts is increasingly common and is associated with an increased risk of CAD and, more generally, of adverse cardiovascular events. Although the term peripheral arterial disease (PAD) commonly refers to the localization of atherosclerotic disease in the arterial districts of the lower limbs, in this document, in accordance with the European Society of Cardiology guidelines, the term PAD will be used for all the locations of atherosclerotic disease excluding coronary and aortic ones. The aim of this review is to report updated data on PAD epidemiology, with particular attention to the prevalence and its prognostic impact on patients with CAD. Furthermore, the key points for an appropriate diagnostic framework and a correct pharmacological therapeutic approach are summarized, while surgical/interventional treatment goes beyond the scope of this review.

Published
2024

2. Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon

Author

Luca, F, Oliva, F, Abrignani, M, Di Fusco, S, Gori, M, Giubilato, S, Ceravolo, R, Temporelli, P, Cornara, S, Rao, C, Caretta, G, Pozzi, A, Binaghi, G, Maloberti, A, Di Nora, C, Di Matteo, I, Pilleri, A, Gelsomino, S, Riccio, C, Grimaldi, M, Colivicchi, F, Gulizia, M, Luca F., Oliva F., Abrignani M. G., Di Fusco S. A., Gori M., Giubilato S., Ceravolo R., Temporelli P. L., Cornara S., Rao C. M., Caretta G., Pozzi A., Binaghi G., Maloberti A., Di Nora C., Di Matteo I., Pilleri A., Gelsomino S., Riccio C., Grimaldi M., Colivicchi F., Gulizia M. M., Luca, F, Oliva, F, Abrignani, M, Di Fusco, S, Gori, M, Giubilato, S, Ceravolo, R, Temporelli, P, Cornara, S, Rao, C, Caretta, G, Pozzi, A, Binaghi, G, Maloberti, A, Di Nora, C, Di Matteo, I, Pilleri, A, Gelsomino, S, Riccio, C, Grimaldi, M, Colivicchi, F, Gulizia, M, Luca F., Oliva F., Abrignani M. G., Di Fusco S. A., Gori M., Giubilato S., Ceravolo R., Temporelli P. L., Cornara S., Rao C. M., Caretta G., Pozzi A., Binaghi G., Maloberti A., Di Nora C., Di Matteo I., Pilleri A., Gelsomino S., Riccio C., Grimaldi M., Colivicchi F., and Gulizia M. M.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.

Published
2024

3. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios

Author

Luca, F, Oliva, F, Abrignani, M, Di Fusco, S, Parrini, I, Canale, M, Giubilato, S, Cornara, S, Nesti, M, Rao, C, Pozzi, A, Binaghi, G, Maloberti, A, Ceravolo, R, Bisceglia, I, Rossini, R, Temporelli, P, Amico, A, Calvanese, R, Gelsomino, S, Riccio, C, Grimaldi, M, Colivicchi, F, Gulizia, M, Luca F., Oliva F., Abrignani M. G., Di Fusco S. A., Parrini I., Canale M. L., Giubilato S., Cornara S., Nesti M., Rao C. M., Pozzi A., Binaghi G., Maloberti A., Ceravolo R., Bisceglia I., Rossini R., Temporelli P. L., Amico A. F., Calvanese R., Gelsomino S., Riccio C., Grimaldi M., Colivicchi F., Gulizia M. M., Luca, F, Oliva, F, Abrignani, M, Di Fusco, S, Parrini, I, Canale, M, Giubilato, S, Cornara, S, Nesti, M, Rao, C, Pozzi, A, Binaghi, G, Maloberti, A, Ceravolo, R, Bisceglia, I, Rossini, R, Temporelli, P, Amico, A, Calvanese, R, Gelsomino, S, Riccio, C, Grimaldi, M, Colivicchi, F, Gulizia, M, Luca F., Oliva F., Abrignani M. G., Di Fusco S. A., Parrini I., Canale M. L., Giubilato S., Cornara S., Nesti M., Rao C. M., Pozzi A., Binaghi G., Maloberti A., Ceravolo R., Bisceglia I., Rossini R., Temporelli P. L., Amico A. F., Calvanese R., Gelsomino S., Riccio C., Grimaldi M., Colivicchi F., and Gulizia M. M.

Abstract

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and should be preferred over vitamin K antagonists (VKAs) since they are superior or non-inferior to VKAs in reducing thromboembolic risk and are associated with a lower risk of intracranial hemorrhage (IH). In addition, many factors, such as fewer pharmacokinetic interactions and less need for monitoring, contribute to the favor of this therapeutic strategy. Although DOACs represent a more suitable option, several issues should be considered in clinical practice, including drug–drug interactions (DDIs), switching to other antithrombotic therapies, preprocedural and postprocedural periods, and the use in patients with chronic renal and liver failure and in those with cancer. Furthermore, adherence to DOACs appears to remain suboptimal. This narrative review aims to provide a practical guide for DOAC prescription and address challenging scenarios.

Published
2023

11. [ANMCO Position paper: Cardiovascular disease in women - prevention, diagnosis, treatment and organization of care]

Author

Francese, G. M., Aspromonte, N., Valente, S., Geraci, G., Pavan, D., Bisceglia, I., Caforio, A. L. P., Colavita, A. R., Cutolo, A., De Angelis, M. C., Di Fusco, S. A., Enea, I., Fiscella, D., Frongillo, D., V. G., Ad, Giubilato, S., Giuffrida, C., Ingianni, N., Luca, F., Marcantoni, L., Martinis, F., Marzullo, R., Masciocco, G., Parrini, I., Rakar, S., Resta, M., Riva, L., Rossini, R., Russo, D., Russo, G., Russo, M. G., Scardovi, A. B., De Luca, L., Gabrielli, D., Gulizia, M. M., Oliva, F., and Colivicchi, F.

Subjects
Male, Sex Factors, Cardiovascular Diseases, Risk Factors, Biological differences, Gender differences, Humans, Estrogens, Female, Cardiovascular disease, Prognosis
Abstract

Cardiovascular diseases are still the main cause of death among women despite the improvements in treatment and prognosis achieved in the last 30 years of research. The determinant factors and causes have not been completely identified but the role of "gender" is now recognized. It is well known that women tend to develop cardiovascular disease at an older age than men, and have a high probability of manifesting atypical symptoms not often recognized. Other factors may also co-exist in women, which may favor the onset of specific cardiac diseases such as those with a sex-specific etiology (differential effects of estrogens, pregnancy pathologies, etc.) and those with a different gender expression of specific and prevalent risk factors, inflammatory and autoimmune diseases and cancer. Whether the gender differences observed in cardiovascular outcomes are influenced by real biological differences remains a matter of debate.This ANMCO position paper aims at providing the state of the research on this topic, with particular attention to the diagnostic aspects and to care organization.

Published
2022

12. ANMCO/SICI-GISE/SIC/SIECVI/SIRM Consensus document: Appropriateness of multimodality imaging in cardiovascular disease [Documento di consenso ANMCO/SICI-GISE/SIC/SIECVI/SIRM: Appropriatezza dell’imaging multimodale nelle patologie cardiovascolari]

Author

Nardi, F, Pino, P, Gabrielli, D, Colivicchi, F, Abrignani, M, Amico, A, Aspromonte, N, Benedetto, F, Bertella, E, Boccardi, L, Bucciarelli Ducci, C, Caldarola, P, Campana, M, Caso, P, Citro, R, Costante, A, De Chiara, B, Di Cesare, E, Di Fusco, S, Domenicucci, S, Enea, I, Erba, P, Faganello, G, Favilli, S, Geraci, G, Giubbini, R, Giunta, N, Guido, V, Imazio, M, Khoury, G, La Canna, G, Mele, D, Moreo, A, Mercuro, G, Musumeci, G, Neglia, D, Parrini, I, Pinamonti, B, Pollarolo, L, Pontone, G, Privitera, C, Riccio, C, Sinagra, G, Urbinati, S, Varbella, F, Berisso, M, Zuin, G, Di Lenarda, A, Gulizia, M, Nardi F., Pino P. G., Gabrielli D., Colivicchi F., Abrignani M. G., Amico A. F., Aspromonte N., Benedetto F. A., Bertella E., Boccardi L. M., Bucciarelli Ducci C., Caldarola P., Campana M., Caso P., Citro R., Costante A. M., De Chiara B. C., Di Cesare E., Di Fusco S. A., Domenicucci S., Enea I., Erba P., Faganello G., Favilli S., Geraci G., Giubbini R., Giunta N., Guido V., Imazio M., Khoury G., La Canna G., Mele D., Moreo A. M., Mercuro G. G., Musumeci G., Neglia D., Parrini I., Pinamonti B., Pollarolo L., Pontone G., Privitera C., Riccio C., Sinagra G., Urbinati S., Varbella F., Berisso M. Z., Zuin G., Di Lenarda A., Gulizia M. M., Nardi, F, Pino, P, Gabrielli, D, Colivicchi, F, Abrignani, M, Amico, A, Aspromonte, N, Benedetto, F, Bertella, E, Boccardi, L, Bucciarelli Ducci, C, Caldarola, P, Campana, M, Caso, P, Citro, R, Costante, A, De Chiara, B, Di Cesare, E, Di Fusco, S, Domenicucci, S, Enea, I, Erba, P, Faganello, G, Favilli, S, Geraci, G, Giubbini, R, Giunta, N, Guido, V, Imazio, M, Khoury, G, La Canna, G, Mele, D, Moreo, A, Mercuro, G, Musumeci, G, Neglia, D, Parrini, I, Pinamonti, B, Pollarolo, L, Pontone, G, Privitera, C, Riccio, C, Sinagra, G, Urbinati, S, Varbella, F, Berisso, M, Zuin, G, Di Lenarda, A, Gulizia, M, Nardi F., Pino P. G., Gabrielli D., Colivicchi F., Abrignani M. G., Amico A. F., Aspromonte N., Benedetto F. A., Bertella E., Boccardi L. M., Bucciarelli Ducci C., Caldarola P., Campana M., Caso P., Citro R., Costante A. M., De Chiara B. C., Di Cesare E., Di Fusco S. A., Domenicucci S., Enea I., Erba P., Faganello G., Favilli S., Geraci G., Giubbini R., Giunta N., Guido V., Imazio M., Khoury G., La Canna G., Mele D., Moreo A. M., Mercuro G. G., Musumeci G., Neglia D., Parrini I., Pinamonti B., Pollarolo L., Pontone G., Privitera C., Riccio C., Sinagra G., Urbinati S., Varbella F., Berisso M. Z., Zuin G., Di Lenarda A., and Gulizia M. M.

Abstract

The complexity of cardiovascular diseases has led to an extensive use of technological instruments and the development of multimodality imaging. This extensive use of different cardiovascular imaging tests in the same patient has increased costs and waiting times.The concept of appropriateness has changed over time. Appropriateness criteria address the need for specific cardiovascular imaging tests in well-defined clinical scenarios, and define the kind of cardiovascular imaging that is appropriated for each clinical scenario in different stages of the disease. The concept of appropriateness criteria has replaced the old idea of appropriate use criteria and reflects the increasing effort of the international Scientific Societies to create and review in a critical way the management of diagnostic tests used by clinicians.The aim of this Italian consensus document is to address the use of multimodality imaging in the diagnosis and management of the major cardiovascular clinical scenarios, taking into consideration not only the international guidelines and scientific documents already published, but also the reality of Italian laws as well as the various professional profiles involved in patient management and availability of technological diagnostic instruments.

Published
2020

19. ANOMALY OF ORIGIN AND COURSE OF THE CIRCUMFLEX ARTERY: AN ECHOCARDIOGRAPHIC DIAGNOSIS

Author

Marino, G, Di Fusco, S, Cianfrocca, C, and Colivicchi, F

Abstract

Coronary artery anomalies are often incidental findings. Most anomalies are benign, but some can cause sudden death. It is important to identify them especially before invasive procedures and cardiac surgery. The echocardiogram, as in this case report, provides a high diagnostic accuracy. We describe three typical echocardiographic signs that we find when the circumflex artery originates from the right coronary cusp and has a retroaortic course. A 42–year–old man presented to the emergency department with oppressive chest pain at rest lasting 1 h. In his medical history, the patient reported the following cardiovascular risk factors: smoking, family history of coronary heart disease, hypertension, type 2 diabetes mellitus for 10 years and hypercholesterolemia. Electrocardiogram showed sinus rhythm at 70 bpm without signs of myocardial ischemia. Troponin, D–dimer, C–reactive protein were normal in consecutive blood samples. The echocardiogram documented a left ventricle with normal size and wall thickness, preserved systolic function and absence of significant valvular disease and pericardial effusion. Apical 4–chamber view showed a tubular structure on the atrial side of the mitral valve (Figure 1A, RAC sign). The same structure was identified in parasternal short–axis view just below the noncoronary aortic cusp (Figure 1B, crossed aorta). The tubular shape suggested a vascular structure in an anomalous position. In the parasternal long–axis view, a transverse section of this vessel was visible near aortic valve (Figure 1C, bleb sign). Patient underwent coronary angiography due to persistence of symptoms. Angiography did not reveal significant coronary stenoses, but documented anomalies in the origin and course of the coronary arteries. The circumflex artery shared its origin from the right coronary cusp with the right coronary artery and had a retroaortic course while the only anterior descending artery originated from the left coronary cusp. Anomalies of origin and/or course of the coronary arteries can be detected in 1.3% of the population undergoing coronary angiography. On echocardiogram “RAC sign”, “crossed aorta” and “bleb sign” are often misdiagnosed as artefacts, calcifications or catheter. In case of suspected coronary anomalies, CT is the reference diagnostic test. The abnormal origin and course found in our patient are considered benign and not associated with an increased risk of sudden death and myocardial ischemia.

Published
2024
Full Text
View/download PDF

21. ANMCO/GISE/SICCH Inter-Society Consensus Document: Antithrombotic therapy in patients undergoing surgery and/or interventional procedures for valvular heart diseases. How to treat complications

Author

Patane, L., Di Lenarda, A., Aspromonte, N., Bianca, I., Capranzano, P., Di Eusanio, M., Di Fusco, S., Di Tano, G., Gabrielli, D., Garatti, A., Geraci, G., Gerometta, P., Miceli, A., Montalto, A., Musumeci, F., Musumeci, G., Nardi, F., Parolari, A., Pino, P.G., Rubino, A.S., Savini, C., Troise, G., Tarantini, G., Urbinati, S., Varbella, F., and Gulizia, M.M.

Subjects
Settore MED/23 - Chirurgia Cardiaca, Blood coagulation, Cardiac catheterization, Cardiac surgical procedures, Heart valve prosthesis, Platelet aggregation inhibitors, Anticoagulants, Consensus, Female, Fibrinolytic Agents, Heart Valve Diseases, Heart Valve Prosthesis Implantation, Humans, Postoperative Complications, Pregnancy, Pregnancy Complications, Cardiovascular, Thromboembolism, Practice Guidelines as Topic
Published
2019

24. DILATED CARDIOMYOPATHY, GUIDELINES PERSONALIZATION OF CARE

Author

Spinelli, A, Macchiusi, A, Marino, G, Di Fusco, S, Pignalberi, C, and Colivicchi, F

Abstract

The term Dilated cardiomyopathy (CMD) refers to a family of diseases characterized by complex interactions between environment and genetic predisposition. Diagnostic tools as cardiac magnetic resonance imaging (MRI) must be systematically implemented in clinical practice to define the etiological cause and undertake a specific therapeutic treatment. We present the case of a young man with CMD and severe left ventricular dysfunction (ejection fraction, EF: 14%; left ventricular end–diastolic volume (LVEDV): 251 ml/m2; left ventricular end–systolic volume (LVESV): 197 ml/m2. The patient has a family history of sudden cardiac death (SCD). He is affected by a psychiatric pathology (ADHD) and has a history of alcohol and drug addiction. Many diagnostic hypotheses have been considered for etiological research (viral myocarditis, genetic or alcoholic–induced cardiomyopathy, toxic substances such as narcotics and psychiatric drug–induced cardiomyopathy). MRI after 11 days in hospital confirmed FE 14%, LVEDV: 320 ml/m2, LVESV: 275 ml/m2; reduction of the wall thickness at the antero–septal wall to the middle tract; areas of altered signal, hyperintense in T2W sequences, at the left ventricular myocardial wall suspected of myocardial edema, associated with extended signal hyperintensity of periventricular tissue, which show marked enhancement immediately after intravenous contrast agent administration (Fig. 1). The underlying psychiatric pathology and the possibility of poor adherence to the maintenance of the wearable defibrillator did not facilitate the clinical follow–up which should have included the identification of the etiological cause and the appropriate treatment guaranteeing the temporary prevention of SCD. So, it was decided to make a personalized therapeutic choice, the patient underwent implantation of a subcutaneous defibrillator, pending a better diagnostic definition and the possible need of other therapies as cardiac transplantation/implantation of mechanical assistance device.

Published
2024
Full Text
View/download PDF

31. Management strategies and choice of antithrombotic treatment in patients admitted with acute coronary syndrome - Executive summary for clinical practice: Consensus Document of the Regional Chapters of the Italian National Association of Hospital Cardiologists (ANMCO) and of the Italian Society of Emergency Medicine (SIMEU),Strategie assistenziali e scelta della terapia antitrombotica nei pazienti ricoverati con diagnosi di sindrome coronarica acuta - Sintesi operativa per la pratica clinica: Documento congiunto delle Sezioni Regionali del Lazio dell'Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) e della Società Italiana di Medicina di Emergenza-Urgenza (SIMEU)

Author

Uguccioni, M., Pugliese, F., Luca, L., Tubaro, M., Ruggieri, M. P., Colivicchi, F., Ammirati, F., Ansalone, G., Avella, A., Azzolini, P., Bertazzoni, G., Brama, P., Cacciatore, G., Luca, M., Simone, M., Di Fusco, S. A., Ferraiuolo, G., Ferranti, F., Granatelli, A., Loschiavo, P., Mezzanotte, R., Mirante, E., Monti, F., Pajes, G., Pandolfo, L., Proietti, F., Revello, A., Stefano Rigattieri, Sabetta, F., Sciahbasi, A., Scioli, R., Serdoz, R., Susi, B., Vincentelli, G. M., Zuccalà, G., and Zulli, L.

32. Polypill Strategy in Secondary Cardiovascular Prevention.

Author

Castellano, J. M., Pocock, S. J., Bhatt, D. L., Quesada, A. J., Owen, R., Fernandez-Ortiz, A., Sanchez, P. L., Marin Ortuño, F., Vazquez Rodriguez, J. M., Domingo-Fernández, A., Lozano, I., Roncaglioni, M. C., Baviera, M., Foresta, A., Ojeda-Fernandez, L., Colivicchi, F., Di Fusco, S. A., Doehner, W., Meyer, A., and Schiele, F.

Abstract

BACKGROUND A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting-enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary prevention of cardiovascular death and complications after myocardial infarction. METHODS In this phase 3, randomized, controlled clinical trial, we assigned patients with myocardial infarction within the previous 6 months to a polypill-based strategy or usual care. The polypill treatment consisted of aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg). The primary composite outcome was cardiovascular death, nonfatal type 1 myocardial infarction, nonfatal ischemic stroke, or urgent revascularization. The key secondary end point was a composite of cardiovascular death, nonfatal type 1 myocardial infarction, or nonfatal ischemic stroke. RESULTS A total of 2499 patients underwent randomization and were followed for a median of 36 months. A primary-outcome event occurred in 118 of 1237 patients (9.5%) in the polypill group and in 156 of 1229 (12.7%) in the usual-care group (hazard ratio, 0.76; 95% confidence interval [CI], 0.60 to 0.96; P=0.02). A key secondary-outcome event occurred in 101 patients (8.2%) in the polypill group and in 144 (11.7%) in the usual-care group (hazard ratio, 0.70; 95% CI, 0.54 to 0.90; P=0.005). The results were consistent across prespecified subgroups. Medication adherence as reported by the patients was higher in the polypill group than in the usual-care group. Adverse events were similar between groups. CONCLUSIONS Treatment with a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction resulted in a significantly lower risk of major adverse cardiovascular events than usual care. (Funded by the European Union Horizon 2020; SECURE ClinicalTrials.gov number, NCT02596126; EudraCT number, 2015-002868-17.) [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Update on Management of Cardiovascular Diseases in Women

Author

Fabiana Lucà, Maurizio Giuseppe Abrignani, Iris Parrini, Stefania Angela Di Fusco, Simona Giubilato, Carmelo Massimiliano Rao, Laura Piccioni, Laura Cipolletta, Bruno Passaretti, Francesco Giallauria, Angelo Leone, Giuseppina Maura Francese, Carmine Riccio, Sandro Gelsomino, Furio Colivicchi, Michele Massimo Gulizia, Luca, F., Abrignani, M. G., Parrini, I., Di Fusco, S. A., Giubilato, S., Rao, C. M., Piccioni, L., Cipolletta, L., Passaretti, B., Giallauria, F., Leone, A., Francese, G. M., Riccio, C., Gelsomino, S., Colivicchi, F., and Gulizia, M. M.

Subjects
SEX-BASED DIFFERENCES, cardiovascular risk factors, GENDER-DIFFERENCES, IRON-DEFICIENCY ANEMIA, General Medicine, POLYCYSTIC-OVARY-SYNDROME, 2021 ESC GUIDELINES, Cardiovascular risk factor, ESTROGEN PLUS PROGESTIN, MYOCARDIAL-INFARCTION, cardiovascular disease, ESC WORKING GROUP, gender, CORONARY-HEART-DISEASE, women, PRIMARY PREVENTION, RISK-FACTOR CONTROL
Abstract

Cardiovascular diseases (CVD) have a lower prevalence in women than men; although, a higher mortality rate and a poorer prognosis are more common in women. However, there is a misperception of CVD female risk since women have commonly been considered more protected so that the real threat is vastly underestimated. Consequently, female patients are more likely to be treated less aggressively, and a lower rate of diagnostic and interventional procedures is performed in women than in men. In addition, there are substantial sex differences in CVD, so different strategies are needed. This review aims to evaluate the main gender-specific approaches in CVD.

Published
2022
Full Text
View/download PDF

34. Appropriate use of wearable defibrillators with multiparametric evaluation to avoid unnecessary defibrillator implantation.

Author

Matteucci A, Pignalberi C, Di Fusco S, Aiello A, Aquilani S, Nardi F, and Colivicchi F

Subjects
Humans, Male, Female, Middle Aged, Follow-Up Studies, Aged, Defibrillators, Implantable, Unnecessary Procedures, Risk Factors, Treatment Outcome, Wearable Electronic Devices, Electric Countershock instrumentation, Electric Countershock adverse effects, Death, Sudden, Cardiac prevention & control, Death, Sudden, Cardiac etiology, Defibrillators, Arrhythmias, Cardiac therapy, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac physiopathology
Abstract

Introduction: Wearable cardioverter-defibrillators (WCD) have emerged as a valuable tool in the management of patients at risk for life-threatening arrhythmias. These devices offer a non-invasive and temporary solution, providing continuous monitoring and the potential for prompt defibrillation when needed. In this study, we explore the use of WCD and evaluate arrhythmic events through comprehensive monitoring., Methods: From November 2022 to May 2024, we conducted an outpatient follow-up of 41 patients receiving WCD. Regular check-ups, remote monitoring and comprehensive echocardiography were performed to optimise a tailored therapy., Results: The average age of the patients was 59.2.4±16.5 years, with 78% being male. Among the cohort, 54% had hypertension, 41% were smokers and 66% had dyslipidaemia, while 27% were diabetic. WCD was assigned according to the Italian Association of Hospital Cardiologists position paper focussing on the appropriate use of WCD and European Society of Cardiology guidelines on ventricular arrhythmias and the prevention of sudden cardiac death: 24 (58%) patients had a de novo diagnosis of heart failure with reduced ejection fraction, 11 (27%) patients had a recent acute coronary syndrome and ejection fraction <35%, 3 (7%) patients had a cardiac electronic device extraction and 3 (7%) patients had myocarditis with features of electrical instability. The average follow-up was 62±38 days according to specific aetiology, with a daily wearing time of 22.7±1.3 hours. No device interventions were recorded. At the end of the follow-up period, 15 patients still required an implantable cardioverter-defibrillator (ICD). Among these, 12 patients (29%) underwent ICD implantation. Two patients (5%) declined the procedure., Conclusions: The use of WCD for patients at high risk of arrhythmias allowed to optimise therapy and limit the indications for ICD. Inappropriate implantation of ICD was avoided in 69% of patients who received WCD. The device showed a good safety profile, low incidence of device interventions and adequate patients' adherence to WCD use., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

35. Tailored care for cardiac health: risk stratification and gentamicin-infused collagen sponges to minimize cardiac device infections and healthcare costs.

Author

Matteucci A, Pandozi C, Pignalberi C, Lavalle C, Mariani MV, Di Fusco SA, and Colivicchi F

Subjects
Humans, Prosthesis-Related Infections prevention & control, Prosthesis-Related Infections economics, Collagen, Aged, Risk Assessment, Male, Female, Middle Aged, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents economics, Gentamicins administration & dosage, Health Care Costs statistics & numerical data
Published
2024
Full Text
View/download PDF

36. Corrigendum: Cardio-oncology in the COVID Era (Co & Co): The never-ending story.

Author

Bisceglia I, Canale ML, Gallucci G, Turazza FM, Lestuzzi C, Parrini I, Russo G, Maurea N, Quagliariello V, Oliva S, Angela Di Fusco S, Lucà F, Tarantini L, Trambaiolo P, Moreo A, Geraci G, Gabrielli D, Gulizia MM, Oliva F, and Colivicchi F

Abstract

[This corrects the article DOI: 10.3389/fcvm.2022.821193.]., (© 2023 Bisceglia, Canale, Gallucci, Turazza, Lestuzzi, Parrini, Russo, Maurea, Quagliariello, Oliva, Angela Di Fusco, Lucà, Tarantini, Trambaiolo, Moreo, Geraci, Gabrielli, Gulizia, Oliva and Colivicchi.)

Published
2023
Full Text
View/download PDF

37. [ANMCO Position paper: Amyloidosis for the clinical cardiologist. A "clinical primer" from the ANMCO Rare Disease Working Group].

Author

Chimenti C, Grego S, Di Fusco S, De Luca L, Caldarola P, Cannillo M, Cipriani M, Di Lenarda A, Donato D, Leone S, Limongelli G, Navazio A, Riccio C, Valente S, Gulizia MM, Gabrielli D, Oliva F, and Colivicchi F

Subjects
Humans, Prealbumin therapeutic use, Amyloid therapeutic use, Rare Diseases, Amyloid Neuropathies, Familial complications, Amyloid Neuropathies, Familial diagnosis, Amyloid Neuropathies, Familial genetics, Cardiologists
Abstract

Cardiac amyloidosis, in the three forms of immunoglobulin light chain (AL), transthyretin (ATTR) wild type (ATTRwt) and mutated (ATTRv) amyloidosis, is an increasingly known and recognized disease in the cardiovascular setting. The first stage of the patient's journey is the clinical suspicion of the disease, which is placed, in presence of a hypertrophic phenotype, by the identification of red flags, both extracardiac and cardiac clues whose presence increase the probability of being faced with a patient with this disease. The second stage is represented by diagnosis, which occurs with certainty through the identification of amyloid substance in cardiac tissue. This stage is spotted in wo parts, i.e. disease confirmation and disease etiology definition (AL vs ATTRwt vs ATTRv). However, it is possible in some selected cases to make a diagnosis of ATTR without the need for tissue assessment, in presence of a positive grade 2-3 bisphosphonate scintigraphy and absence of monoclonal component. Once the diagnosis has been made, the third stage is the assessment of prognosis, the fourth is the patient therapy pathway and fifth is the follow-up plan. Prognosis evaluation is based on different staging systems at the onset of the disease, whose applicability in the era of new effective therapies is still to be defined. To date, the transthyretin tetramer stabilizer tafamidis is the only approved treatment for both wild-type and mutant ATTR cardiomyopathy without polyneuropathy, while ATTRv with associated neuropathy can benefit from treatment with patisiran, an inhibitor of hepatic protein synthesis. Therapies for complications and comorbidities, must be addressed individually, due to the lack of specific clinical trials on this category of patients. In fact, it is important to take into consideration the risks linked to the use of some drugs due to the infiltration of the conduction tissue by the amyloid substance, which increases the risk of bradycardia and heart blocks, the tendency towards hypotension and the increased thromboembolic risk. It is also essential to follow the course of the disease and the efficacy of the treatment in affected patients with a standardized follow-up, and to identify early the signs/symptoms of the disease in asymptomatic TTR mutation carriers.This ANMCO position paper on amyloidosis aims to provide the clinical cardiologist with a practical summary of the disease, to accompany the patient with amyloidosis in the various stages of his journey.

Published
2023
Full Text
View/download PDF

38. ANMCO POSITION PAPER: Prognostic and therapeutic relevance of non-obstructive coronary atherosclerosis.

Author

Casolo G, Gabrielli D, Colivicchi F, Murrone A, Grosseto D, Gulizia MM, Di Fusco S, Domenicucci S, Scotto di Uccio F, Di Tano G, Orso F, Grippo G, Abrignani M, Valente S, and Corda M

Abstract

Atherosclerosis often affects the coronary arterial tree. Frequently the disease does not translate in significant narrowing of the vessels, thus determining only a non-obstructive disease. This condition that is described as non-obstructive coronary artery disease (NobsCAD) should be distinguished from the absence of disease (i.e. smooth coronary arteries) as it carries a specific prognostic value. The detection and reporting of NobsCAD should prompt preventive measures that can be individualized upon the degree of the underlying burden of disease. The accompanying clinical condition, the other cardiovascular risk factors present, and the description of the severity and extent of NobsCAD should provide the framework for an individualized treatment that should also consider the best available scientific evidence and guidelines. The description of NobsCAD represents important information to be collected whenever a coronary angiogram (both invasive and non-invasive) is performed. Treating the patient according to the presence and extent of NobsCAD offers prognostic benefits well beyond those offered by considering only the traditional cardiovascular risk factors. In order to reach this goal, NobsCAD should not be confused with the absence of coronary atherosclerosis or even ignored when detected as if it was a trivial information to provide., (Published on behalf of the European Society of Cardiology. © The Author(s) 2021.)

Published
2021
Full Text
View/download PDF

39. [ANMCO/GISE/SICCH Inter-Society Consensus Document: Antithrombotic therapy after surgery or structural interventional procedures for valvular heart diseases: how to treat postoperative complications].

Author

Patanè L, Di Lenarda A, Aspromonte N, Bianca I, Capranzano P, Di Eusanio M, Di Fusco S, Di Tano G, Gabrielli D, Garatti A, Geraci G, Gerometta P, Miceli A, Montalto A, Musumeci F, Musumeci G, Nardi F, Parolari A, Pino PG, Rubino AS, Savini C, Troise G, Tarantini G, Urbinati S, Varbella F, and Gulizia MM

Subjects
Anticoagulants administration & dosage, Consensus, Female, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation methods, Humans, Postoperative Complications physiopathology, Pregnancy, Pregnancy Complications, Cardiovascular surgery, Thromboembolism etiology, Thromboembolism prevention & control, Fibrinolytic Agents administration & dosage, Heart Valve Diseases surgery, Postoperative Complications drug therapy, Practice Guidelines as Topic
Abstract

Continuous improvement of technologies, devices and drugs needs a renewal and update of current recommendations and guidelines on antithrombotic strategies, especially in those fields where literature lacks of established scientific evidences. Accordingly, the aim of this consensus statement is to provide support for antithrombotic therapy based on current guidelines and the most recent scientific evidences.After an overview on the currently available devices, the appropriate therapy according to type of procedure and implanted device is discussed. The occurrence of postoperative thromboembolic and/or hemorrhagic complications is analyzed, along with the appropriate diagnostic tools and therapeutic approach. A section is dedicated to counseling to pregnancy in women with heart valve prosthesis. Finally, the role of novel oral anticoagulants is discussed, and indications are provided for the management of patients undergoing surgery or interventional procedures on oral anticoagulation therapy.

Published
2019
Full Text
View/download PDF

40. Hydroquinidine therapy in Brugada syndrome.

Author

Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheney P, Di Fusco S, Rey JL, Cauchemez B, and Leenhardt A

Subjects
Adolescent, Adult, Aged, Arrhythmias, Cardiac complications, Cohort Studies, Death, Sudden, Cardiac etiology, Death, Sudden, Cardiac prevention & control, Female, Humans, Male, Middle Aged, Treatment Outcome, Ventricular Fibrillation etiology, Ventricular Fibrillation prevention & control, Anti-Arrhythmia Agents therapeutic use, Arrhythmias, Cardiac drug therapy, Quinidine analogs & derivatives, Quinidine therapeutic use
Abstract

Objectives: We sought to assess hydroquinidine (HQ) efficacy in selected patients with Brugada syndrome (BrS)., Background: Management of asymptomatic patients with BrS and inducible arrhythmias remains a key issue. Effectiveness of class Ia antiarrhythmic drugs, which inhibit the potassium transient outward current of the action potential, has been suggested in BrS., Methods: From a cohort of 106 BrS patients, we studied 35 who received HQ (32 men; mean age 48 +/- 11 years). Patients had asymptomatic BrS and inducible arrhythmia (n = 31) or multiple appropriate shocks from an implantable cardioverter-defibrillator (ICD) (n = 4). Asymptomatic patients with inducible arrhythmia underwent electrophysiologic (EP)-guided therapy. When ventricular tachycardia (VT)/ventricular fibrillation (VF) inducibility was not prevented, or in case of HQ intolerance, an ICD was placed., Results: Hydroquinidine prevented VT/VF inducibility in 76% of asymptomatic patients who underwent EP-guided therapy. Syncope occurred in two of the 21 patients who received long-term (17 +/- 13 months) HQ therapy (1 syncope associated with QT interval prolongation and 1 unexplained syncope associated with probable noncompliance). In asymptomatic patients who received an ICD (n = 10), one appropriate shock occurred during a follow-up period of 13 +/- 8 months. In patients with multiple ICD shocks, HQ prevented VT/VF recurrence in all cases during a mean follow-up of 14 +/- 8 months., Conclusions: Hydroquinidine therapy prevented VT/VF inducibility in 76% of asymptomatic patients with BrS and inducible arrhythmia, as well as VT/VF recurrence in all BrS patients with multiple ICD shocks. These preliminary data suggest that preventive treatment by HQ may be an alternative strategy to ICD placement in asymptomatic patients with BrS and inducible arrhythmia.

Published
2004
Full Text
View/download PDF

41. [Brugada syndrome].

Author

Leenhardt A, Hamdaoui B, Di Fusco S, Extramiana F, Meddane M, Denjoy I, Milliez P, Dejode P, and Cauchemez B

Subjects
Algorithms, Arrhythmias, Cardiac genetics, Arrhythmias, Cardiac pathology, Bundle-Branch Block genetics, Bundle-Branch Block pathology, Defibrillators, Implantable, Electrocardiography, Humans, Mutation, Patient Care Planning, Prognosis, Syndrome, Arrhythmias, Cardiac complications, Bundle-Branch Block complications, Syncope etiology
Abstract

The Brugada syndrome is characterised clinically by the occurrence of syncope or sudden death due to ventricular arrhythmias in patients with structurally normal hearts and electrocardiographic signs of right bundle branch block and ST elevation in the right precordial leads (V1 to V3). The transmission of the condition is autosomal dominant with variable penetration. Mutations have been identified in a gene coding for the alpha sub-unity of the sodium channel (SCN5A) on chromosome 3 in only 30% of cases. This mutation is responsible for a reduction of the density of the sodium current and explains the aggravation of the electrocardiographic anomalies by antiarrhythmic drugs which block the sodium channels. The prognosis is poor in symptomatic patients and depends on the prevention of sudden death by the implantation of an automatic defibrillator. The therapeutic decision is much more difficult in asymptomatic patients without a family history. The authors propose a decisional algorithm. The management may have to be modified in the months or years to come depending on advances in the understanding of this syndrome.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results